p53 degradation
p53 Degradation Activity, Expression, and Subcellular Localization of E6 Proteins from 29 Human Papillomavirus Genotypes
14
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
14
Proteasome Activator REGγ Enhances Coxsackieviral Infection by Facilitating p53 Degradation
11
Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells.
6
CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression
13
Multiple Functions of Human Papillomavirus Type 16 E6 Contribute to the Immortalization of Mammary Epithelial Cells
11
Genetic Analysis of High-Risk E6 in Episomal Maintenance of Human Papillomavirus Genomes in Primary Human Keratinocytes
6
An RNA aptamer targets the PDZ-binding motif of the HPV16 E6 oncoprotein.
17
Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice
15
The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest.
8
Regulation of p53: a collaboration between Mdm2 and MdmX
8
Review Article New insights into regulation of p53 protein degradation
7
Peptide Interactions Stabilize and Restructure Human Papillomavirus Type 16 E6 To Interact with p53
6
hAda3 Degradation by Papillomavirus Type 16 E6 Correlates with Abrogation of the p14ARF-p53 Pathway and Efficient Immortalization of Human Mammary Epithelial Cells
9
High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation.
8
Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes.
5
Human Papillomavirus E6 Regulates the Cytoskeleton Dynamics of Keratinocytes through Targeted Degradation of p53
5
Addressing intra-tumoral heterogeneity and therapy resistance
21
Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins.
6
Mutant p53 protects ETS2 from non-canonical COP1/DET1 dependent degradation
14